Core Insights - Arcturus Therapeutics' stock plummeted over 55% following mixed results from a monthlong study of its experimental cystic fibrosis treatment using mRNA technology [1][3] - The study indicated no significant improvement in forced expiratory volume (FEV), a critical measure for cystic fibrosis patients, although some patients showed reduced mucous burden [2][3] - Analysts have differing opinions on the results, with one suggesting potential clinical benefits at high doses, while another described the data as underwhelming [3] Company Performance - Arcturus Therapeutics' stock fell to $10.27 after previously rising 188% from a low of $8.04 in April [3] - The company had a strong IBD Digital Relative Strength Rating of 92, placing it in the top 8% of all stocks based on 12-month performance [3] Analyst Commentary - William Blair analyst Myles Minter noted potential for clinical benefit at high doses [3] - Leerink Partners analyst Lili Nsongo characterized the data as underwhelming, reflecting a cautious outlook on the treatment's efficacy [3]

Core Insights - Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) fell by over 56% following the release of interim results from its Phase 2 study of ARCT-032, an inhaled mRNA therapy [1] Company Summary - The significant drop in share price indicates a negative market reaction to the interim results of the clinical trial [1] - ARCT-032 is positioned as an inhaled mRNA therapy, which suggests a focus on innovative delivery methods in the biotechnology sector [1] Industry Context - The incident highlights the volatility and risks associated with clinical trial results in the biotechnology industry, particularly for companies developing novel therapies [1]

Company Overview - Arcturus Therapeutics (ARCT) shares increased by 7.7% to $23.16 in the last trading session, with a higher-than-average trading volume [1] - The stock has gained 2.3% over the past four weeks [1] Pipeline and Development - The positive investor sentiment is linked to ARCT's pipeline, which includes two mRNA therapeutic candidates: ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032 for cystic fibrosis, both in mid-stage development [2] - Arcturus has partnered with CSL Seqirus to develop Kostaive, the world's first sa-mRNA COVID-19 vaccine, which is approved in Japan and the EU [2] Financial Expectations - The company is expected to report a quarterly loss of $1.09 per share, reflecting a year-over-year decline of 319.2% [3] - Projected revenues for the upcoming quarter are $16.67 million, down 60% from the same quarter last year [3] Earnings Estimates and Stock Performance - The consensus EPS estimate for Arcturus has remained unchanged over the last 30 days, indicating a lack of upward revisions [4] - The stock's price typically does not continue to rise without trends in earnings estimate revisions, suggesting the need for monitoring future performance [4] - Arcturus currently holds a Zacks Rank of 1 (Strong Buy) [4] Industry Comparison - In the same industry, Septerna, Inc. (SEPN) saw a 5% decrease in its stock price, closing at $21.31, but has returned 40.3% over the past month [4] - Septerna's consensus EPS estimate has remained unchanged at $0.19, representing a 102.3% increase from the previous year, and it holds a Zacks Rank of 3 (Hold) [5]

Core Insights - U.S. stock markets are experiencing a continued upward trend in 2025, following a strong rally over the past two years, with expectations for the Fed to lower benchmark lending rates due to a weak labor market [1][2] Market Sentiment - Recent U.S. government shutdown and delays in key economic data releases may dampen investor enthusiasm, alongside trade conflicts with China affecting market sentiment [2] - Despite these challenges, some stocks have shown price strength, particularly those on a recent bull run, indicating potential for continued momentum [2][3] Stock Screening - Four stocks identified with recent price strength include Flux Power Holdings Inc. (FLUX), Aura Minerals Inc. (AUGO), Arcturus Therapeutics Holdings Inc. (ARCT), and Sterling Infrastructure Inc. (STRL) [3][8] - The screening criteria for these stocks include: - Percentage Change in Price (4 Weeks) greater than zero - Percentage Change in Price (12 Weeks) greater than 10 - Zacks Rank 1 (Strong Buy) - Average Broker Rating of 1 - Current Price greater than $5 - Current Price/52-Week High-Low Range more than 85% [5][6][7] Individual Stock Performance - **Flux Power Holdings Inc. (FLUX)**: Stock price increased by 92.1% in four weeks, with an expected earnings growth rate of 82.4% for the current year, and earnings estimates rising by 40% over the past 60 days [8][9] - **Aura Minerals Inc. (AUGO)**: Stock price climbed 9.3% in four weeks, with an expected earnings growth rate exceeding 100% for the current year, and earnings estimates improving by 2.5% over the past week [10][11] - **Arcturus Therapeutics Holdings Inc. (ARCT)**: Stock price advanced 2.3% in four weeks, with an expected earnings growth rate of -10% for the current year, and earnings estimates improving by 11.5% over the past 90 days [11][12] - **Sterling Infrastructure Inc. (STRL)**: Stock price gained 0.4% in four weeks, with an expected earnings growth rate of 56.9% for the current year, and earnings estimates improving by 9.7% over the past 60 days [13][15]

Core Viewpoint - The article emphasizes the importance of identifying and sustaining stock price trends for successful short-term investing, highlighting the need for strong fundamentals and positive earnings revisions to maintain momentum [1][2]. Group 1: Stock Performance - Arcturus Therapeutics (ARCT) has shown a significant price increase of 46.3% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also experienced a 17.5% price increase in the last four weeks, suggesting that the upward trend is still intact [5]. - ARCT is currently trading at 84.9% of its 52-week high-low range, indicating a potential breakout opportunity [5]. Group 2: Fundamental Strength - ARCT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like ARCT that are on an upward trend supported by strong fundamentals [3][8]. - It also mentions the availability of over 45 Zacks Premium Screens tailored to different investing styles, which can help in finding potential winning stocks [8].

Group 1 - Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock has experienced a rise of slightly above 20% this month, resulting in double-digit gains [1] - The company previously thrived during the COVID boom due to large upfront payments and government contracts, which drove peak revenues and visibility [1] Group 2 - The current performance of Arcturus Therapeutics indicates a potential recovery or growth phase following the pandemic-related surge [1]

Company Overview - Arcturus Therapeutics (ARCT) shares increased by 8.7% to close at $19.62, with trading volume significantly higher than usual, contrasting with a 4% gain over the past four weeks [1][2] Pipeline and Product Development - The recent stock uptick is driven by positive investor sentiment regarding ARCT's pipeline, which includes two mRNA therapeutic candidates: ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032 for cystic fibrosis, both in mid-stage development [2] - Arcturus has partnered with CSL Seqirus to develop Kostaive, the world's first sa-mRNA COVID-19 vaccine, which is currently approved in Japan and the EU [2] Financial Performance Expectations - The company is expected to report a quarterly loss of $1.09 per share, reflecting a year-over-year decline of 319.2%, with revenues projected at $16.67 million, down 60% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 13% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] Industry Context - Arcturus Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Anika Therapeutics (ANIK) also operates, having closed 3.2% higher at $8.94, with a 3.5% return over the past month [4] - Anika's consensus EPS estimate for its upcoming report remains unchanged at $0.02, representing a year-over-year increase of 108%, and it holds a Zacks Rank of 2 (Buy) [5]

Group 1 - Arcturus Therapeutics Holdings Inc. (ARCT) has reached a key level of support, with a recent "golden cross" occurring as its 50-day simple moving average crossed above its 200-day simple moving average, indicating a potential bullish breakout [1] - The golden cross pattern consists of three stages: a downtrend that bottoms out, the shorter moving average crossing above the longer moving average, and a subsequent upward price movement [2] - ARCT shares have increased by 38.3% over the past four weeks, and the company holds a 3 (Hold) rating on the Zacks Rank, suggesting a potential for further breakout [3] Group 2 - There have been four upward changes in ARCT's earnings expectations for the current quarter over the past 60 days, with no downward changes, indicating a positive trend in earnings estimates [3] - The combination of rising earnings estimates and positive technical indicators suggests that investors may want to monitor ARCT for potential gains in the near future [4]

Core Insights - Arcturus Therapeutics Holdings Inc. held its Q2 2025 Earnings Conference on August 11, 2025, featuring key executives including the CEO and CFO [1][2][3]. Company Overview - The conference call was led by Joseph E. Payne, President and CEO, and Andrew H. Sassine, CFO, with Dr. Pad Chivukula, CSO and COO, participating in the Q&A session [3]. Financial Update - The call was part of Arcturus Therapeutics' quarterly financial update and pipeline progress, indicating ongoing developments in their business operations [3]. Investor Relations - Neda Safarzadeh, Vice President and Head of Investor Relations, Public Relations, and Marketing, facilitated the conference, highlighting the company's commitment to transparency with investors [2][3].

Company Performance - Arcturus Therapeutics reported a quarterly loss of $0.34 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.11, representing an earnings surprise of +69.37% [1] - The company posted revenues of $28.3 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 20.84%, although this is a decline from $49.86 million in the same quarter last year [2] - Over the last four quarters, Arcturus has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Arcturus Therapeutics shares have declined approximately 29.8% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Arcturus is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$1.12 on revenues of $20.92 million, and for the current fiscal year, it is -$3.73 on revenues of $70.59 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Arcturus operates, is currently in the bottom 41% of over 250 Zacks industries, which may impact the stock's performance [8]